Sentinel node biopsy in node negative early oral cancers: Solution to the conundrum!. (November 2022)

• Record Type: Journal Article
• Authors: Vaish, Richa; Mittal, Neha; Mahajan, Abhishek; Rane, Swapnil U; Agrawal, Archi; D'Cruz, Anil K
• Is Part Of: Oral oncology. Volume 134(2022)
• Publication Date: 2022-11
• Subjects: Biopsy, sentinel lymph node -- Neck dissection -- Survival analysis -- Morbidity -- Pathology, surgical; Mouth -- Cancer -- Periodicals; Mouth -- Tumors -- Periodicals; Mouth Diseases -- Periodicals; Mouth Neoplasms -- Periodicals; Bouche -- Cancer -- Périodiques; Bouche -- Tumeurs -- Périodiques; Tumeurs -- Périodiques; Electronic journals; 616.9943105
• DOI: 10.1016/j.oraloncology.2022.106070
• Languages: English
• ISSNs: 1368-8375

Abstract

Highlights: Management of N0 neck in early oral cancers have enthralled researchers for decades. SNB is an oncologically safe procedure in this cohort and limits the morbidity. Widespread applicability of SNB is limited due to resource and logistic constraints. Important to overcome these limitations for global acceptability. Understand biology, find novel solutions, implement lessons learnt from other sites. Abstract: Ideal management of the node-negative neck in early oral cancers is a debated issue. Elective neck dissection (END) is recommended in these patients as it offers a survival benefit. However, about 50–70% of patients who do not harbor occult metastasis are overtreated with this approach. Surgery is associated with morbidity, predominantly shoulder dysfunction. Numerous attempts have been made to identify true node-negative patients through imaging and prediction models but none have high diagnostic accuracy to safely spare the neck dissection. The recent publications of 2 large randomized controlled trials comparing the outcomes of sentinel node biopsy (SNB) and END have spurred interest in SNB. Both the trials reported SNB to be an oncologically safe procedure and spared unnecessary neck dissections. The functional outcomes of the trials showed that SNB limits the morbidity compared to END, which albeit evens out at the end of one-year post-surgery. Despite its benefits, SNB has failed to gain widespread acceptability due to various limitations including the need for infrastructure, equipment costs, staff, and multidisciplinary collaboration of nuclear medicine, surgical, and pathology fraternity. The labor-intensive pathology protocol with serial step sectioning and immunohistochemistry poses a challenge to the feasibility at a high-volume center. This perspective discusses these limitations and propose plausible solutions to the conundrum. To make it widely applicable and feasible across the globe efforts should be directed to understand biology better, find novel solutions, and implement the lessons learned over decades from other sites.